JenniferAWrightMD

Pediatric Hematology & Oncology • Salt Lake City, UT

Assistant Professor, Pediatrics, University of Utah School of Medicine

Join to view full profile

Are you Dr. Wright?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 35 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
100 N Mario Capecchi Dr
Salt Lake City, UT 84113
Phone+1 801-662-4700

Summary

Dr. Jennifer Wright, MD is a pediatric hematologist/oncologist in Salt Lake City, Utah. She is currently licensed to practice medicine in Utah and Indiana. She is affiliated with University of Utah Health and Primary Children's Hospital.

Education & Training

University of Texas Southwestern Medical CenterFellowship, Pediatric Hematology/Oncology, 2004 - 2007
Indiana University School of MedicineResidency, Internal Medicine/Pediatrics, 2000 - 2004
Indiana University School of MedicineClass of 2000

Certifications & Licensure

IN State Medical License 2002 - 2023
UT State Medical License 2007 - 2018

Clinical Trials

Metformin in Children With Relapsed or Refractory Solid Tumors Start of enrollment: 2012 Sep 24
Completed
Phase 1
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma Start of enrollment: 2012 Aug 01
Completed
Phase 2
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies Start of enrollment: 2013 Jan 01
Completed
Phase 1
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Start of enrollment: 2014 Jul 01
Completed
Phase 2
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Start of enrollment: 2014 Mar 21
Completed
Phase 3
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Start of enrollment: 2016 Mar 01
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
The Effect of Gastrointestinal Graft-Versus-Host Disease and Diarrhea on the Pharmacokinetic Profile of Sotrovimab in Hematopoietic Stem Cell Transplant Recipients.
Jim Boonyaratanakornkit, Qianwen Wang, Ahmed Nader, Louise Kimball, Terry Stevens-Ayers
The Journal of Infectious Diseases. 2024-09-23
15 citations
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.
Steven Attia, Vanessa Bolejack, Kristen N Ganjoo, Suzanne George, Mark Agulnik
Cancer Medicine. 2023-01-01
152 citations
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2,...
Vivek Subbiah, Jürgen Wolf, Bhavana Konda, Hyunseok Kang, Alexander Spira
The Lancet. Oncology. 2022-10-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member